Business / Finance

RSS

Unigene acquires exclusive worldwide rights to oral PTH program from GSK

Unigene Laboratories, Inc. today announced that the Company terminated its amended and restated exclusive worldwide license agreement and related development services and clinical supply agreement with GlaxoSmithKline (GSK) pertaining to an oral formulation of a recombinantly produced parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

5 Dec 2011

Hi-Tech Pharmacal second quarter net sales increase 27% to 56,875,000

Hi-Tech Pharmacal Co., Inc. today reported results for the Company's fiscal second quarter ended October 31, 2011.

5 Dec 2011

InfraReDx receives $10M senior secured multi-draw term loan from GE Capital

GE Capital, Healthcare Financial Services announced today that it was the sole lender on a $10 million senior secured multi-draw term loan to InfraReDx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases. The financing will be used to help support product commercialization efforts.

5 Dec 2011

Acadia prices 8.3 million public offering

Acadia Healthcare Company, Inc. today announced a public offering of 8,333,333 shares of its common stock, pursuant to a registration statement filed with the Securities and Exchange Commission.

5 Dec 2011

Millipore reports redemption completion of outstanding 3.75% Convertible Senior Notes Due 2026

Millipore Corporation, the Life Science business of Merck KGaA of Germany, that operates as EMD Millipore in the U.S. and Canada, today announced that all its remaining outstanding 3.75% Convertible Senior Notes Due 2026 (the "Notes") were redeemed on December 1, 2011, at one hundred percent (100%) of the outstanding principle amount of the Notes.

3 Dec 2011

Pfizer acquires Excaliard

Pfizer Inc. announced today that it has completed its acquisition of Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring.

3 Dec 2011

Teavana third quarter net sales increase 35% to $33.4 million

Teavana Holdings, Inc. today announced financial results for the third quarter and fiscal year-to-date ended October 30, 2011.

2 Dec 2011

GE Healthcare invests in C8 MediSensors to focus on disease management solutions

GE Capital and GE Healthcare, the financial services and healthcare divisions of General Electric Company, announced today an investment in C8 MediSensors, Inc., a privately held developer of non-invasive continuous glucose monitors for diabetic patients.

2 Dec 2011

Corning acquires Mediatech

Great Point Partners today announced that Great Point Partners I portfolio company, Mediatech, Inc., was acquired by Corning Incorporated in an all-cash transaction. Mediatech is now a wholly-owned subsidiary of Corning and will be integrated into Corning's Life Science segment.

2 Dec 2011

Global external defibrillators market to grow at 6% CAGR to exceed $2.2 billion by 2017

Global Information, Inc. (GII) presents "External Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017" by GlobalData.

2 Dec 2011

Bausch + Lomb announces acquisition of Pfortner Cornealent SACIF

Bausch + Lomb, the global eye health company, today announced it has acquired 100 percent of the outstanding shares of Laboratorio Pfortner Cornealent SACIF, the controlling entity of Waicon.

2 Dec 2011

Agilent expands life sciences business with two strategic acquisitions

Agilent Technologies Inc. today announced it is expanding its life sciences business with two strategic acquisitions.

2 Dec 2011

MergerTech launches $50M venture capital fund for healthcare IT

MergerTech Advisors is excited to announce the launch of 'MergerTech Capital', a new $50 million venture capital fund. The fund will focus on the investment and development of healthcare IT product and services firms, building on the sectors' substantial potential for extraordinary growth and creativity.

2 Dec 2011

Novelos prices underwritten public offering of $5,904,000 of common stock

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced the pricing of an underwritten public offering of 9,840,000 units at $0.60 per unit for gross proceeds of $5,904,000.

2 Dec 2011

Pfizer acquires Ferrosan Consumer Health's business

Pfizer Inc. today announced that it has completed its previously announced acquisition of Ferrosan Consumer Health's business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited.

1 Dec 2011

Corning completes acquisition of Mediatech

Corning Incorporated announced today that it has completed the acquisition of Mediatech, Inc., a Virginia-based corporation, including Mediatech's subsidiary, KD Medical, Inc., a Maryland-based corporation.

1 Dec 2011

Lipitor going generic, Pfizer making deals to keep consumers

The popular cholesterol-lowering drug Lipitor goes off-patent today. Manufacturer Pfizer planned ahead, making agreements with some insurers to keep covering the drug.

1 Dec 2011

arGEN-X closes EUR 27.5 million Series B fundraising round

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announced today the closing of a EUR 27.5 million (USD 37 million) Series B fundraising round, which was oversubscribed.

1 Dec 2011

Ranbaxy and Teva announce generic Lipitor agreement

Teva Pharmaceutical Industries Ltd. announced today that pursuant to an agreement between its subsidiary, Teva Pharmaceuticals USA, Inc. and Ranbaxy Laboratories Limited, a portion of the profits from Ranbaxy's sales of Atorvastatin Calcium Tablets during Ranbaxy's 180-day first-to-file exclusivity period, will be paid to Teva.

1 Dec 2011

Affymetrix signs definitive agreement to acquire eBioscience

Affymetrix, Inc., today announced that it has signed a definitive agreement to acquire eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics. Under the terms of the agreement, Affymetrix will acquire eBioscience for $330 million in cash subject to certain customary adjustments.

30 Nov 2011